Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma

Pirtobrutinib with venetoclax and rituximab is currently in clinical development for the treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have been previously treated with at least one prior line of therapy. CLL and SLL are types of cancer in which too many white blood cells (B-cells) are produced, these cells build up in the lymph nodes, blood, and bone marrow. As these cells develop abnormally, they are unable to function and fight infection and might reduce the production of healthy blood cells. These diseases are chronic and develop slowly. Over time this can cause a range of problems, such as an increased risk of developing infections, persistent tiredness, swollen glands in the neck, armpits or groin, and unusual bleeding or bruising. Most patients develop resistance to the currently available treatment options, creating a need for novel therapies for this condition.